Pharmacological characterization of A-131701, a novel α1-adrenoceptor antagonist selective for α(1A)- and α(1D)-compared to α(1B)-adrenoceptors

Drug Development Research

Volumn 44, Issue 4, 1998, Pages 140-162

  Hancock, Arthur A ^a   Buckner, Steven A ^a   Brune, Michael E ^a   Katwala, Sweta ^a   Milicic, Ivan ^a   Ireland, Lynne M ^a   Morse, Patricia A ^a   Knepper, Sheila M ^a   Meyer, Michael D ^a   Chapple, Christopher R ^b   Chess Williams, Russell ^c   Noble, Amanda J ^c   Williams, Michael ^a   Kerwin Jr , James F ^a  

^a ABBOTT LABORATORIES   (United States)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

1 adrenoceptor; 1 adrenoceptor antagonist; 1 adrenoceptor subtype(s); Benign prostatic hyperplasia

Indexed keywords

3 [2 (2,3,3A,4,5,9B HEXAHYDRO 6 METHOXY 1H BENZ[E]ISOINDOL 2 YL)ETHYL]PYRIDO[3',4':4,5]THIENO[3,2 D]PYRIMIDINE 2,4(1H,3H) DIONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; DOXAZOSIN; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; DOG; DRUG BINDING SITE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; HAMSTER; HUMAN; HYPERTENSION; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TACHYCARDIA;

EID: 7844227696     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199808)44:4<140::AID-DDR2>3.0.CO;2-R     Document Type: Article

References (60)

1. 1-adrenoceptors and uroselectivity. Prostate 30:202-215.
2. Altwein JE (1995): Introduction: The changing therapy of benign prostatic hyperplasia. Scand J Urol Nephrol 29:1-6.
3. Barry M, Roehrborn, C (1997): Management of benign prostatic hyperplasia. Annu Rev Med 48:177-189.
4. Brune ME, Buckner SA, Polakowski J, Kerwin JF, Hancock AA (1995): Pharmacological antagonism of α-adrenergic agonist induced increases in canine intra-urethral pressure in vivo. Drug Dev Res 34:267-275.
5. 1D-subtype. Em J Pharmacol 297:241-248.
6. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U (1994): IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136.
7. 1b-adrenergic receptor. Proc Natl Acad Sci USA 94:11589-11594.
8. 1-adrenocepror subtypes in the human prostate. Br J Urol 74:585-589.
9. 1A-adrenoceptor antagonist: A metaanalysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29:155-167.
10. 1-adrenoceptor. Br J Pharmacol 119:1093-1100.
11. 1-adrenergic receptor antagonists for the treatment of hypertension: Role of vascular alpha receptors in the control of peripheral resistance. Am Heart J 116:133-162.
12. DeLean A, Munson PJ, Rodbard D (1978): Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay and physiological dose-response curves. Am J Physiol 235:E97-E102.
13. 1-adrenoceptors. Eur J Pharmacol 73:221-224.
14. 1A-AR antagonist, RS 17053. Br J Urol 114(Suppl):P24.
15. 1c-subtype. Mol Pharmacol 45:703-708.
16. Fulton B, Wagstaff AJ, Sorkin EM (1995): Doxazosin: An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 49:295-320.
17. 1-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. Eur J Med Chem 30(Suppl):S299-S310.
18. 1-Adrenoceptor subtypes: A synopsis of their pharmacology and molecular biology, Drug Dev Res 39:54-107.
19. 2-adrenoceptors in vitro. J Recept Signal Transduct Res 15:863-885.
20. 1B-adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity. J Pharmacol Exp Ther 285:628-642.
21. 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol 97:691-700.
22. 3H]prazosin binding sites. J Pharm Pharmacol 41:714-716.
23. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113:723-728.
24. Hatano A, Tang R, Walden PD, Lepor H (1996): The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. Eur J Pharmacol 313:135-143.
25. Hieble JP, Boyce AJ, Caine M (1986): Comparison of the α-adrenoceptor characteristics in human and canine prostate. Fed Proc 45:2609-2614.
26. Hieble JP, Bondinell WE, Ruffolo RR Jr (1995): α- and ß-Adrenoceptors: From the gene to the clinic. 1. Molecular biology and adrenoceptor Subclassification. J Med Chem 38:3415-3444.
27. 1A-adrenoceptor isoforms in membranes and whole cells. Pharmacologist 39:39 (Abstract 103).
28. Kawabe K (1993): Analysis of alpha-1 adrenoceptors in human prostate. Aktuelle Urol 24:82-85.
29. Kawabe K (1995): Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 76(S1):63-67.
30. 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology 44: 52-57.
31. 1 adrenoceptors: Binding, functional and in vivo studies. Br J Pharmacol 118:871-878.
32. Kenny B, Ballard S, Blagg J, Fox D (1997): Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem 40: 1293-1315.
33. Kirby RS (1997): Medical therapy for benign prostatic hyperplasia: The road ahead. Br J Urol 79(Suppl 1):92-96.
34. 1-A receptor subtype. J Pharmacol Exp Ther 274:97-103.
35. 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats. J Autonom Pharmacol 12:191-204.
36. Leonardi A, Hieble JP, Guarneri L, Naselsky DP Poggesi E, Sironi G, Sulpizio AC, Testa R (1997): Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharm Exp Ther 281:1272-1283.
37. Lepor H, Tang R, Shapiro E (1993): The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 22:301-307.
38. Lepor H, Willford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ (1996): The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Engl J Med 335:533-539.
39. Luther RR (1989): Therapeutic review: Terazosin: A new antihypertensive agent with favorable effects on lipids. Int J Clin Pharmacol Ther Toxicol 27:313-319.
40. 1c-) adrenoceptor subtype. Br J Pharmacol 115:781-786.
41. Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I (1997): Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharm Exp Ther 282:228-235.
42. 1D-adrenoceptors in prostatic contraction examined using protections studies. Br J Pharmacol 120(Suppl):108P.
43. 1-Adrenoceptor properties of terazosin HC1 and its enantiomers in the human prostate and canine brain. Prostate 20:159-165.
44. 1A-subtype in rat submaxillary gland. Br J Pharmacol 98:883-889.
45. 1-adrenoceptors in noradrenaline contraction of the rabbit thoracic aorta. Br J Pharmacol 101:662-666.
46. 1-adrenoceptor subtypes in the human prostate: Functional and binding studies. Br J Urol 74:572-578.
47. 1D-adrenoceptor subtypes, Br J Pharmacol 120:231-238.
48. 1 adrenergic receptor subtypes in human prostate. J Urol 150:546-551.
49. 1A-receptors. Eur J Med Chem 28:499-504.
50. Ruffolo RR Jr, Bondinell WE, Hieble JP (1995): α- and β-Adrenoceptors: From the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem 38:3415-3444.
51. Schild HO (1947): pA, a new scale for the measurement of drug antagonism. Br J Pharmacol 2:189-206.
52. 1A-adrenoceptor antagonist: Analysis of a multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29:145-154.
53. Snedecor GW, Cochran WG (1967): Statistical Methods, Ames, Iowa: Iowa State University Press.
54. Tallarida RJ, Jacob LS (1979): The dose-response relation in pharmacology. New York: Springer-Verlag.
55. 1-adrenoceptor subtypes in human prostate: Comparison with those in rat vas deferens and spleen. Eur J Pharmacol 265:61-66.
56. 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man, Eur J Pharmacol 249:307-315.
57. Testa R, Guarneri L, Taddei C, Poggesi E, Angelico P, Sartani A, Leonardi A, Gofrit ON, Meretyk S, Gaine M (1996): Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther 277:1237-1246.
58. Testa R, Guarneri L, Angelico P, Poggesi E, Taddei C, Sironi G, Columbo D, Sulpizio AC, Naselsky DP, Hieble JP, Leonardi A (1997): Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): Role of alpha-IL adrenoceptor in tissue selectivity, part II. J Pharm Exp Ther 281:1272-1283.
59. 1c-adrenoceptor in human prostate: Cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol 115:1475-1485.
60. 1D-adrenoreptor (sic) protein detectable in rat tissues? Naunyn Schmiedebergs Arch Pharmacol 355:438-446.